Literature DB >> 28682536

Ketamine for Depression, 3: Does Chirality Matter?

Chittaranjan Andrade1.   

Abstract

Ketamine is a racemic mixture of the enantiomers R-ketamine and S-ketamine (esketamine). S-ketamine has greater analgesic and anesthetic effects than R-ketamine and is less likely to cause psychotomimetic and other adverse effects. There is therefore an emerging interest favoring the use of S-ketamine over racemic ketamine when the drug is used for analgesia or anesthesia. This article examines preclinical and clinical literature on the antidepressant properties of S-ketamine. Animal data suggest potential advantages for R-ketamine over S-ketamine. Case reports, case series, and some small randomized controlled trials suggest that single or repeated intravenous infusions (0.2-0.4 mg/kg) or intranasal administrations (28-84 mg) of S-ketamine have antidepressant action in patients with medication-refractory depression and that the observed benefits are similar in magnitude to the antidepressant benefits reported with racemic ketamine. However, there are no direct comparisons between S-ketamine and either R-ketamine or racemic ketamine in depressed patients; therefore, it is not possible to make an informed choice when considering the enantiomers and the racemate for the indication of depression. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28682536     DOI: 10.4088/JCP.17f11681

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

Review 1.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 2.  Role of Ketamine in the Treatment of Psychiatric Disorders.

Authors:  Sahar Derakhshanian; Maxine Zhou; Alexander Rath; Rachel Barlow; Sarah Bertrand; Caroline DeGraw; Christopher Lee; Jamal Hasoon; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-22

3.  Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography.

Authors:  Marie Spies; Gregory M James; Neydher Berroterán-Infante; Harald Ibeschitz; Georg S Kranz; Jakob Unterholzner; Mathis Godbersen; Gregor Gryglewski; Marius Hienert; Johannes Jungwirth; Verena Pichler; Birgit Reiter; Leo Silberbauer; Dietmar Winkler; Markus Mitterhauser; Thomas Stimpfl; Marcus Hacker; Siegfried Kasper; Rupert Lanzenberger
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

4.  A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry.

Authors:  T S Sathyanarayana Rao; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2017 Jul-Sep       Impact factor: 1.759

5.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

6.  Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial.

Authors:  Fernanda S Correia-Melo; Gustavo C Leal; Michelle S Carvalho; Ana Paula Jesus-Nunes; Carolina B N Ferreira; Flávia Vieira; Guilherme Magnavita; Lucas A S Vale; Rodrigo P Mello; Carolina Nakahira; Felipe C Argolo; Tanise Cardoso; Cezar D S Souza; Ana Teresa C Fontes; Marcelo B Ferreira; Lucas Araújo-de-Freitas; Marco A Tuena; Mariana V F Echegaray; Diogo E Cavalcanti; Ana C Lucchese; Igor D Bandeira; Manuela Telles; Cássio S Lima; Aline S Sampaio; Samantha S Silva; Roberta F Marback; José A Del-Porto; José Neander Abreu; Luciana M Sarin; Camilla S Paixão; Lucas P Carvalho; Paulo R L Machado; Gustavo Turecki; Acioly L T Lacerda; Lucas C Quarantini
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

Review 7.  A Review of the Mechanism of Antagonism of N-methyl-D-aspartate Receptor by Ketamine in Treatment-resistant Depression.

Authors:  Yasar Sattar; John Wilson; Ali M Khan; Mahwish Adnan; Daniel Azzopardi Larios; Shristi Shrestha; Quazi Rahman; Zeeshan Mansuri; Ali Hassan; Nirav B Patel; Nargis Tariq; Sharaad Latchana; Stefany C Lopez Pantoja; Sadiasept Vargas; Naveed A Shaikh; Fawaduzzaman Syed; Daaman Mittal; Fatima Rumesa
Journal:  Cureus       Date:  2018-05-18

Review 8.  Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.

Authors:  Domenico De Berardis; Michele Fornaro; Alessandro Valchera; Marilde Cavuto; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Annastasia Fiengo; Antonio Ventriglio; Kim Yong-Ku; Giovanni Martinotti; Massimo Di Giannantonio; Carmine Tomasetti
Journal:  Int J Mol Sci       Date:  2018-09-23       Impact factor: 5.923

Review 9.  On the safety of repeated ketamine infusions for the treatment of depression: Effects of sex and developmental periods.

Authors:  C E Strong; Mohamed Kabbaj
Journal:  Neurobiol Stress       Date:  2018-09-21

Review 10.  The evolutionary old forebrain as site of action to develop new psychotropic drugs.

Authors:  Anton Jm Loonen; Svetlana A Ivanova
Journal:  J Psychopharmacol       Date:  2018-09-26       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.